Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is a biotech company with promising prospects, as it focuses on the research and development of therapies for multiple types of cancers, viral diseases, and immune-deficiency disorders. Its ongoing Phase 2 clinical trial for Ampligen in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor shows potential for the treatment of metastatic pancreatic cancer, a disease with a high mortality rate. With multiple clinical trials underway and a current focus on pancreatic cancer, AIM ImmunoTech presents a high risk-high reward opportunity for investors.

Bears say

AIM ImmunoTech is currently facing several challenges such as balance sheet/liquidity risks, lack of commercial success for its product candidates, and strong competition in the biotech industry. Additionally, upcoming clinical data releases may not meet expectations, further impacting investor sentiment and ability to gain regulatory approvals. The company will need to address these issues and demonstrate strong clinical success in order to improve its outlook and attain its share price target.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.